Since tumor cells frequently inactivate the mitochondrial death pathway in order to acquire therapy resistance (e.g., by elevated levels of antiapoptotic Bcl-2), these meriolin derivatives display a favorable option for overcoming treatment resilience. This evidence concerns the gene BCL2 and neoplasm.